PH12022552815A1 - 5-membered heteroaryl carboxamide compounds for treatment of hbv - Google Patents
5-membered heteroaryl carboxamide compounds for treatment of hbvInfo
- Publication number
- PH12022552815A1 PH12022552815A1 PH1/2022/552815A PH12022552815A PH12022552815A1 PH 12022552815 A1 PH12022552815 A1 PH 12022552815A1 PH 12022552815 A PH12022552815 A PH 12022552815A PH 12022552815 A1 PH12022552815 A1 PH 12022552815A1
- Authority
- PH
- Philippines
- Prior art keywords
- hbv
- membered heteroaryl
- treatment
- carboxamide compounds
- heteroaryl carboxamide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Metal-Oxide And Bipolar Metal-Oxide Semiconductor Integrated Circuits (AREA)
- Thin Film Transistor (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063014001P | 2020-04-22 | 2020-04-22 | |
| PCT/US2021/028323 WO2021216656A1 (en) | 2020-04-22 | 2021-04-21 | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12022552815A1 true PH12022552815A1 (en) | 2024-03-25 |
Family
ID=75919388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2022/552815A PH12022552815A1 (en) | 2020-04-22 | 2021-04-21 | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
Country Status (14)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240089748A (ko) * | 2021-10-20 | 2024-06-20 | 어셈블리 바이오사이언시스, 인크. | 방법 |
| JP2024541124A (ja) * | 2021-10-20 | 2024-11-06 | アセンブリー・バイオサイエンシーズ・インコーポレイテッド | 新規結晶形態 |
| WO2023069544A1 (en) * | 2021-10-20 | 2023-04-27 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
| WO2023069545A1 (en) * | 2021-10-20 | 2023-04-27 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
| WO2023069547A1 (en) * | 2021-10-20 | 2023-04-27 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
| EP4448492B1 (en) | 2021-12-17 | 2026-03-04 | Reglagene, Inc. | Compositions and methods of making and using small molecules in the treatment of cancer |
| JP7894535B2 (ja) | 2023-02-28 | 2026-07-23 | レグラジーン、インコーポレイテッド | 健康状態の治療のための小分子を作製および使用するための組成物および方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013006394A1 (en) | 2011-07-01 | 2013-01-10 | Institute For Hepatitis And Virus Research | Sulfamoylbenzamide derivatives as antiviral agents against hbv infection |
| US9968650B2 (en) | 2011-07-13 | 2018-05-15 | Indiana University Research And Technology Corporation | Modified viral structural protein with antiviral activity |
| AR089671A1 (es) | 2012-01-06 | 2014-09-10 | Janssen R & D Ireland | 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b |
| CA2881057C (en) | 2012-08-28 | 2020-10-27 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
| NZ704758A (en) | 2012-08-28 | 2018-06-29 | Janssen Sciences Ireland Uc | Fused bicyclic sulfamoyl derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| CA2881322A1 (en) | 2012-09-10 | 2014-03-13 | F. Hoffmann-La Roche Ag | 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
| HK1215030A1 (zh) | 2012-11-09 | 2016-08-12 | Indiana University Research And Technology Corporation | 用於hbv組裝效應劑的替代用途 |
| CN104918612B (zh) | 2012-12-06 | 2019-10-25 | 巴鲁克斯布隆伯格研究所 | 作为抗hbv感染的抗病毒剂的官能化苯甲酰胺衍生物 |
| HK1217649A1 (zh) | 2012-12-27 | 2017-01-20 | 德雷克塞尔大学 | 針對hbv感染的新型抗病毒劑 |
| JP6466348B2 (ja) | 2013-02-28 | 2019-02-06 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | スルファモイル−アリールアミドおよびb型肝炎を処置するための医薬品としてのその使用 |
| HUE033542T2 (en) | 2013-04-03 | 2017-12-28 | Janssen Sciences Ireland Uc | Their use as medicaments for the treatment of N-phenylcarboxamide derivatives and hepatitis B |
| TW202126620A (zh) | 2013-05-17 | 2021-07-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | 胺磺醯基吡咯醯胺衍生物及其作為用於治療b型肝炎藥物的用途 |
| HUE040446T2 (hu) * | 2013-05-17 | 2019-03-28 | Janssen Sciences Ireland Uc | Szulfamoiltiofenamid-származékok és gyógyszerként történõ alkalmazásuk hepatitis B kezelésére |
| PE20151951A1 (es) | 2013-05-17 | 2015-12-26 | Hoffmann La Roche | Heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b |
| WO2015011281A1 (en) * | 2013-07-25 | 2015-01-29 | Janssen R&D Ireland | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| ES2748029T3 (es) * | 2014-03-13 | 2020-03-12 | Univ Indiana Res & Tech Corp | Moduladores alostéricos de proteína núcleo de hepatitis B |
| TWI730985B (zh) * | 2015-09-15 | 2021-06-21 | 美商艾森伯利生物科學公司 | B型肝炎核心蛋白質調節劑 |
| KR102398439B1 (ko) * | 2016-03-07 | 2022-05-16 | 이난타 파마슈티칼스, 인코포레이티드 | B형 간염 항바이러스제 |
| TW201806956A (zh) * | 2016-06-29 | 2018-03-01 | 諾維拉治療公司 | 二氮呯酮衍生物及治療b型肝炎感染之方法 |
| AU2017326356A1 (en) * | 2016-09-15 | 2019-04-11 | Assembly Biosciences, Inc. | Hepatitis B core protein modulators |
| WO2019076358A1 (en) | 2017-10-19 | 2019-04-25 | Js Innopharm (Shanghai) Ltd | HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF |
| SG11202104086PA (en) * | 2018-10-22 | 2021-05-28 | Assembly Biosciences Inc | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
| WO2021216660A1 (en) * | 2020-04-22 | 2021-10-28 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
-
2021
- 2021-04-21 AU AU2021261307A patent/AU2021261307B2/en active Active
- 2021-04-21 CN CN202610120828.3A patent/CN122167357A/zh active Pending
- 2021-04-21 MX MX2022013251A patent/MX2022013251A/es unknown
- 2021-04-21 CN CN202511217514.7A patent/CN121248511A/zh active Pending
- 2021-04-21 CN CN202180042939.2A patent/CN115843294B/zh active Active
- 2021-04-21 BR BR112022021419A patent/BR112022021419A2/pt unknown
- 2021-04-21 PH PH1/2022/552815A patent/PH12022552815A1/en unknown
- 2021-04-21 KR KR1020227040228A patent/KR20230005881A/ko active Pending
- 2021-04-21 WO PCT/US2021/028323 patent/WO2021216656A1/en not_active Ceased
- 2021-04-21 JP JP2022564258A patent/JP7830347B2/ja active Active
- 2021-04-21 AR ARP210101072A patent/AR121905A1/es unknown
- 2021-04-21 IL IL297305A patent/IL297305B1/en unknown
- 2021-04-21 EP EP21725867.2A patent/EP4139292A1/en active Pending
- 2021-04-21 CA CA3180706A patent/CA3180706A1/en active Pending
- 2021-04-21 US US17/920,544 patent/US12655130B2/en active Active
- 2021-04-22 TW TW110114601A patent/TW202206415A/zh unknown
-
2022
- 2022-10-20 MX MX2026003747A patent/MX2026003747A/es unknown
-
2025
- 2025-09-19 JP JP2025156540A patent/JP2025186437A/ja active Pending
-
2026
- 2026-05-28 AU AU2026204148A patent/AU2026204148A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230005881A (ko) | 2023-01-10 |
| EP4139292A1 (en) | 2023-03-01 |
| JP2023523241A (ja) | 2023-06-02 |
| US20230183213A1 (en) | 2023-06-15 |
| US12655130B2 (en) | 2026-06-16 |
| CN122167357A (zh) | 2026-06-09 |
| MX2022013251A (es) | 2022-11-14 |
| CN115843294B (zh) | 2026-02-10 |
| JP2025186437A (ja) | 2025-12-23 |
| AR121905A1 (es) | 2022-07-20 |
| AU2021261307A1 (en) | 2022-11-17 |
| IL297305B1 (en) | 2026-05-01 |
| AU2026204148A1 (en) | 2026-06-11 |
| JP7830347B2 (ja) | 2026-03-16 |
| CN115843294A (zh) | 2023-03-24 |
| CN121248511A (zh) | 2026-01-02 |
| MX2026003747A (es) | 2026-05-04 |
| WO2021216656A1 (en) | 2021-10-28 |
| BR112022021419A2 (pt) | 2023-03-07 |
| TW202206415A (zh) | 2022-02-16 |
| CA3180706A1 (en) | 2021-10-28 |
| AU2021261307B2 (en) | 2026-06-18 |
| IL297305A (en) | 2022-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021550887A1 (en) | 5-membered heteroaryl carboxamide compounds for treatment of hbv | |
| MX2022013251A (es) | Compuestos de heteroaril carboxamida de 5 miembros para el tratamiento de vhb. | |
| PH12019502003A1 (en) | Cyclic sulfamide compounds and methods of using same | |
| ATE512976T1 (de) | Hemmer des hepatitis-c-virus | |
| CR20240223A (es) | Compuestos terapéuticos para la infección por el virus del vih | |
| NO20045247L (no) | Nukleosidderivater for behandling av hepatitt C-virusinfeksjon | |
| GEP20084545B (en) | Introducing tlr7 ligands and prodrugs thereof for the treatment of hepatitis c viral infection | |
| MX2025002439A (es) | Compuestos ciclicos de urea tiazolilo para el tratamiento del hsv | |
| NO20062428L (no) | Kombinasjoner for HCV-behandling | |
| DE60225316D1 (en) | Cyanoalkylamino-derivate als protease-hemmer | |
| NO20051969L (no) | Nukleosidderivater for behandling av hepatitt C virusinfeksjon. | |
| TW200518746A (en) | Novel inhibitors of hepatitis C virus NS3/NS4A serine protease | |
| MX2021007602A (es) | Derivados de heteroarildihidropirimidina y metodos de tratamiento de infecciones de hepatitis b. | |
| PH12021552870A1 (en) | Compositions and methods for treating hepatitis b virus (hbv) infection | |
| MX2021010145A (es) | Derivados de amida utiles en el tratamiento de una infeccion por vhb o de enfermedades inducidas por vhb. | |
| NZ510369A (en) | Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection | |
| PH12021550632A1 (en) | Monomer and multimeric anti-hbv agents | |
| JOP20210313A1 (ar) | مشتقات حلقية غير متجانسة مندمجة | |
| WO2022173714A3 (en) | Antibodies that bind metapneumovirus, antigenic metapneumovirus proteins, and uses thereof | |
| MX2025009837A (es) | Compuestos de benzotia(dia)zepina para el tratamiento del vhb y el vhd | |
| ATE498398T1 (de) | Cycloalkyl-heterozyklen zur behandlung des hepatitis-c-virus | |
| EP4247800C0 (en) | N-SUBSTITUTED 4-(1,3-ARYLOXAZOLO-2-YL)PHENYL COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | |
| WO2021202317A3 (en) | Novel methods of using nitric oxide donor compounds for treatment of covid-19 and other infectious diseases | |
| EA202191220A1 (ru) | НОВЫЕ МОЧЕВИНО-6,7-ДИГИДРО-4H-ПИРАЗОЛО[4,3-с]ПИРИДИНЫ, АКТИВНЫЕ ПРОТИВ ВИРУСА ГЕПАТИТА В (HBV) | |
| EA202191221A1 (ru) | НОВЫЕ МОЧЕВИНО-6,7-ДИГИДРО-4H-ТИАЗОЛО[5,4-c]ПИРИДИНЫ, АКТИВНЫЕ ПРОТИВ ВИРУСА ГЕПАТИТА В (HBV) |